161 related articles for article (PubMed ID: 31775478)
1. [Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia].
Wang CJ; Huang XJ; Gong LZ; Jia JS; Liu XH; Wang Y; Yan CH; Chang YJ; Zhao XS; Shi HX; Lai YY; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):812-817. PubMed ID: 31775478
[No Abstract] [Full Text] [Related]
2. [Clinical Safety of NK Cell in the Prevention of Leukemia Relapse Post-transplantation and in Treatment of the Elderly Leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
6. [Effect of NCCN (2015) risk stratification on prognosis of patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Wang H; Liu HX; Wang T; Tong CR; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):44-49. PubMed ID: 28219225
[No Abstract] [Full Text] [Related]
7. [Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease].
Zhang YM; Zhang Y; Ni X; Gao L; Qiu HY; Zhang YS; Tang GS; Chen J; Zhang WP; Wang JM; Yang JM; Hu XX
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):16-22. PubMed ID: 32023749
[No Abstract] [Full Text] [Related]
8. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic Factors and Predictive Value of MRD before Consolidation Therapy in Middle-risk Newly Diagnosed Young and Middle-aged Patients with AML].
Niu ZY; Dang HB; Yue L; Tian QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):462-468. PubMed ID: 33812416
[TBL] [Abstract][Full Text] [Related]
11. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
Gaut D; Oliai C; Boiarsky J; Zhang S; Salhotra A; Azenkot T; Kennedy VE; Khanna V; Olmedo Gutierrez K; Shukla N; Moskoff B; Park G; Afkhami M; Patel A; Jeyakumar D; Mannis G; Logan AC; Jonas BA; Schiller G
Leuk Lymphoma; 2024 Jan; 65(1):69-77. PubMed ID: 37801340
[TBL] [Abstract][Full Text] [Related]
13. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
15. [The Role of NK Cells in Allogeneic Hematopoietic Stem Cell Micro-Transplantation for Acute Myeloid leukemia].
Liu RY; Yu CL; Qiao JH; Cai B; Sun QY; Wang Y; Liu TQ; Jiang S; Zhang TY; Ai HS; Guo M; Hu KX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):546-555. PubMed ID: 38660865
[TBL] [Abstract][Full Text] [Related]
16. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
17. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
[TBL] [Abstract][Full Text] [Related]
18. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia.
Muñoz Builes M; Vela Cuenca M; Fuster Soler JL; Astigarraga I; Pascual Martínez A; Vagace Valero JM; Tong HY; Valentín Quiroga J; Fernández Casanova L; Escudero López A; Sisinni L; Blanquer M; Mirones Aguilar I; González Martínez B; Borobia AM; Pérez-Martínez A
BMJ Open; 2020 Jan; 10(1):e029642. PubMed ID: 31919123
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
Kulkarni U; Arunachalam AK; Palani HK; Nair RR; Balasundaram N; Venkatraman A; Korula A; Selvarajan S; Lionel S; Balasubramanian P; Maddali M; Abraham A; George B; Mathews V
Cell Transplant; 2023; 32():9636897231198178. PubMed ID: 37706453
[TBL] [Abstract][Full Text] [Related]
20. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
